Sugi Predict

Sugi Predict / Compounds / SCHEMBL4149104

SCHEMBL4149104

SCHEMBL4149104

CC(C)(C)OC(=O)N1CCCC(Cc2ccc(F)cc2)C1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CCR3 P51677 7/20 0.51
▸ CYP2D6 P10635 4/20 0.51
▸ SCN9A Q15858 1/20 0.48
▸ ACKR3 P25106 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ PSEN1 P49768 1/20 0.47
▸ PSEN2 P49810 1/20 0.47
▸ APH1B Q8WW43 1/20 0.47
▸ NCSTN Q92542 1/20 0.47
▸ APH1A Q96BI3 1/20 0.47
▸ PSENEN Q9NZ42 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ KAT7 O95251 1/20 0.46
▸ KAT8 Q9H7Z6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21358915 1.00 CCR3 (0.51) CCR3CYP2D6SCN9AACKR3ALDH1A1
SCHEMBL20015304 0.91 POLB (0.51) CCR3CYP2D6POLBKMT2A
SCHEMBL29347992 0.89 GPR119 (0.53) CCR3CYP2D6ACKR3ALDH1A1SMN1; SMN2
SCHEMBL8233954 0.88 MAOB (0.52) SCN9AACKR3ALDH1A1SMN1; SMN2KMT2A
SCHEMBL6348614 0.88 CYP2D6 (0.46) CCR3CYP2D6SCN9AACKR3PSEN1
SCHEMBL6353905 0.88 CYP2D6 (0.46) CCR3CYP2D6SCN9AACKR3PSEN1
SCHEMBL6353911 0.88 CYP2D6 (0.46) CCR3CYP2D6SCN9AACKR3PSEN1
SCHEMBL6347744 0.88 CYP2D6 (0.46) CCR3CYP2D6SCN9AACKR3PSEN1
SCHEMBL6348615 0.88 CYP2D6 (0.46) CCR3CYP2D6SCN9AACKR3PSEN1
SCHEMBL6347748 0.88 CYP2D6 (0.46) CCR3CYP2D6SCN9AACKR3PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118955490-A O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors 渤健马萨诸塞州股份有限公司 2024-11-15 — — CN disclosed
CN-112218863-B O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors 比奥根MA公司 2024-07-12 — — CN disclosed
EP-4186899-A1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS Biogen MA Inc. (US) 2023-05-31 — — EP disclosed
EP-4186899-A1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS Biogen MA Inc. (US) 2023-05-31 — — EP disclosed
US-20230117898-A1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. 2023-04-20 — — US disclosed
US-20230117898-A1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. 2023-04-20 — — US disclosed
CN-113508109-B Substituted heterocyclic amide compound, preparation method and medical application thereof 劲方医药科技(上海)有限公司 2023-02-10 — — CN disclosed
EP-3765458-B1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS BIOGEN MA INC (US) 2023-01-11 — — EP disclosed
EP-3765458-B1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS BIOGEN MA INC (US) 2023-01-11 — — EP disclosed
US-11459324-B2 O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors BIOGEN MA INC. (US) 2022-10-04 — — US disclosed
US-20040058961-A1 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity KO SOO S (US) 2004-03-25 — — US disclosed
US-6638950-B2 Antiasthmatics and antiallergens, treating autoimmune pathologies such as rheumatoid arthritis and atherosclerosis BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-10-28 — — US disclosed
US-6627629-B2 Useful for the treatment or prevention of asthma and other allergic diseases. BRISTOL-MYERS SQUIBB PHARMA 2003-09-30 — — US disclosed
CN-1440402-A N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity BRISTOL MYERS SQUIBB PHARMA CO (US) 2003-09-03 — — CN disclosed
EP-1296949-A2 PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Pharma Company (US) 2003-04-02 — — EP disclosed
EP-1296978-A2 N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-02 — — EP disclosed
US-20030032654-A1 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-02-13 — — US disclosed
US-20020156102-A1 Piperidine amides as modulators of chemo kine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-10-24 — — US disclosed
WO-2002002525-A2 N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-01-10 — — WO disclosed
WO-2001098268-A2 PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117898-A1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS MGAT3, ST3GAL3, ST6GAL1 CCR3 1807/4885CYP2D6 477/4885SCN9A 429/4885
US-20020156102-A1 Piperidine amides as modulators of chemo kine receptor activity CCR3, CCR1, ACKR3 CCR3 1/4885CYP2D6 4475/4885SCN9A 1787/4885
US-20040058961-A1 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity CCR3, CCR1, ACKR3 CCR3 1/4885CYP2D6 2961/4885SCN9A 1186/4885
US-20030032654-A1 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity CCR3, CCR1, ACKR3 CCR3 1/4885CYP2D6 2961/4885SCN9A 1186/4885
US-11459324-B2 O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors MGAT3, ST6GAL1, ST3GAL3 CCR3 1954/4885CYP2D6 381/4885SCN9A 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.